Effects of short-acting exenatide added three times daily to insulin therapy on bone metabolism in type 1 diabetes.

Nicklas Järvelä Johansen Thomas Fremming DejgaardAsger LundCamilla SchlüntzBolette HartmannJens J HolstTina VilsbøllHenrik U AndersenFilip K Krag Knop

Published in: Diabetes, obesity & metabolism (2021)

Despite an exenatide-induced body weight reduction, no changes in bone metabolism were observed with exenatide added to insulin therapy in type 1 diabetes after 26 weeks.

Keyphrases

type diabetes
glycemic control
body weight
bone mineral density
insulin resistance
cardiovascular disease
physical activity
stem cells
soft tissue
mesenchymal stem cells
bone regeneration
metabolic syndrome
drug induced
bone loss
diabetic rats
skeletal muscle
weight loss
bone marrow